News

CVS Health stock has returned 74.8% over the past year, yet its broader valuation checks lean expensive, so investors are weighing a strong share price run against signals that the stock may already be pricing in a lot of good news. Over the last 12 months, CVS Health has delivered a 74.8% return, which puts recent holders in a strong position and naturally raises the bar for what future returns need to justify today’s price. Expectations around CVS Health’s ability to grow healthcare and...

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se

(Update with the Justice Department's response to a request for comment in the third paragraph.)

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

Express Scripts, Caremark and Optum Rx sued the FTC after the agency accused them of driving up the cost of insulin. But the countersuit is being put to bed now that the PBMs are settling with regulators.

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.